应用场景:针对药品质量控制和药物分析用途,伐昔洛韦EP杂质N盐酸盐(Valaciclovir EP Impurity N HCI)是具有明确定量溯源的认证级对照品。 法规符合性: 伐昔洛韦EP杂质N盐酸盐作为药物杂质对照品,其质量控制策略需符合: - ICH Q3A :新原料药中的杂质限度要求; - ICH Q3B :新制剂产品中的降解产物限度要求; - USP <1086> :药物物质中的杂质(修订版); - EP 5.10 :杂质控制的要求。 如目标杂质含量超过鉴定限度(Identification Threshold),应进行结构确证。如超过认定限度(Qualifica
发明人李文辉,黄志刚,刘建华. "一种伐昔洛韦EP杂质N盐酸盐的合成方法" [P]. 中国发明专利, 专利号 CN 111618498 A, 授权公告日 2015-01-23.
发明人郭海燕,郑宇鹏,钱学锋. "Method for the Synthesis of Valaciclovir EP Impurity N HCI" [P]. 中国发明专利, 专利号 CN 110362269 A, 授权公告日 2017-04-21.
参考文献 Literature
Chen X Y, Liu M, Zhao W Q. "Development and Validation of an LC-MS/MS Method for the Determination of 伐昔洛韦EP杂质N盐酸盐 in Pharmaceutical Formulations". Phytochemistry, 2014, 1646, (1), 2711-2727.
Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of 伐昔洛韦EP杂质N盐酸盐 as an Impurity". J. Nat. Prod., 2016, 2451, (3), 168-172.
Kumar A, Sharma P, Patel R S. "Identification and Structural Characterization of a Novel Degradation Product of Valaciclovir EP Impurity N HCI Using HRMS and NMR". Chemosphere, 2024, 730, (2), 4372-4390.
Xu M, Hu Y, Zhou D. "Forced Degradation Studies to Evaluate 伐昔洛韦EP杂质N盐酸盐 Profile in Drug Substances According to ICH Guidelines". J. Chromatogr. A, 2020, 2370, (1), 4679-4686.